Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

(Reuters) -Novo Nordisk said on Friday a late-stage trial with a high-dose version of the active ingredient semaglutide, used in its blockbuster obesity drug Wegovy, helped overweight patients ...

Semaglutide is the key ingredient in Novo Nordisk A/S’s (NYSE:NVO) popular drugs, including Wegovy for weight loss and Ozempic for diabetes. Tuesday, Novo Nordisk’s FLOW kidney outcomes trial ...

Novo’s booming semaglutide franchise for diabetes and obesity is the standout inclusion in this year’s list. The U.S. Department of Health and Human Services unveiled the list of 15 drugs Friday.

Novo Nordisk's late stage diabetes candidate semaglutide has scored another victory, outperforming Eli Lilly’s Trulicity in controlling glucose levels and body weight. The phase 3 trial success ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b ...

The recalled drugs comprised semaglutide, which belongs to the GLP-1 class of drugs, and pyridoxine ... company says Ozempic maker Novo Nordisk says it’s the only company in Canada with Health ...

Novo Nordisk has initiated two trials investigating the efficacy of semaglutide 7.2mg, STEP UP and STEP UP T2D. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group ...

Novo Nordisk (NVO) announced Friday that its popular obesity therapy, semaglutide, marketed as Wegovy, led to 20.7% weight loss over 72 weeks at a higher dose of 7.2 mg in a late-stage trial.

Detailed results from Novo's trial testing the higher dose of Wegovy, which contains the active ingredient semaglutide, are expected to be presented at a scientific conference in 2025, according ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...